Floatz logo

MEDI5257

MSI

Assistance Publique - Hôpitaux de ParisPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the MSI cohort.

Asset / SponsorPhaseRating
Cetuximab
Federation Francophone de Cancerologie Digestive
Phase 2B
(+)-VINCRISTINE
Federation Francophone de Cancerologie Digestive
Phase 2B
PANITUMUMAB
Federation Francophone de Cancerologie Digestive
Phase 2B
Irinotecan
Federation Francophone de Cancerologie Digestive
Phase 2B
Aflibercept
Federation Francophone de Cancerologie Digestive
Phase 2B

View all 12 →

Same molecule, other indications

MEDI5257 is also rated in:

colorectal cancerDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →